Atrys Health SL (ATRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atrys Health SL (ATRY) has a cash flow conversion efficiency ratio of 0.026x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€6.22 Million ≈ $7.27 Million USD) by net assets (€241.53 Million ≈ $282.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Atrys Health SL - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Atrys Health SL's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Atrys Health SL for a breakdown of total debt and financial obligations.
Atrys Health SL Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrys Health SL ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Gold Bond Group Ltd
TA:GOLD
|
0.012x |
|
CJ Freshway Corporation
KQ:051500
|
0.071x |
|
Puerto Ventana
SN:VENTANAS
|
-0.928x |
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
|
Monument Mining Limited
V:MMY
|
0.113x |
|
Old Point Financial Corporation
NASDAQ:OPOF
|
0.014x |
|
St Augustine Gold and Copper Ltd
TO:SAU
|
-0.002x |
|
Thejo Engineering Limited
NSE:THEJO
|
0.082x |
Annual Cash Flow Conversion Efficiency for Atrys Health SL (2015–2024)
The table below shows the annual cash flow conversion efficiency of Atrys Health SL from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see ATRY market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €253.24 Million ≈ $296.07 Million |
€3.00 Million ≈ $3.50 Million |
0.012x | +413.87% |
| 2023-12-31 | €289.88 Million ≈ $338.90 Million |
€-1.09 Million ≈ $-1.28 Million |
-0.004x | +91.75% |
| 2022-12-31 | €337.57 Million ≈ $394.66 Million |
€-15.43 Million ≈ $-18.04 Million |
-0.046x | -366.86% |
| 2021-12-31 | €273.98 Million ≈ $320.31 Million |
€4.69 Million ≈ $5.49 Million |
0.017x | +192.45% |
| 2020-12-31 | €75.33 Million ≈ $88.07 Million |
€-1.40 Million ≈ $-1.63 Million |
-0.019x | -168.34% |
| 2019-12-31 | €39.95 Million ≈ $46.71 Million |
€1.08 Million ≈ $1.27 Million |
0.027x | +178.48% |
| 2018-12-31 | €26.44 Million ≈ $30.91 Million |
€-913.68K ≈ $-1.07 Million |
-0.035x | -161.14% |
| 2017-12-31 | €23.30 Million ≈ $27.24 Million |
€1.32 Million ≈ $1.54 Million |
0.057x | +201.57% |
| 2016-12-31 | €14.26 Million ≈ $16.68 Million |
€-793.63K ≈ $-927.84K |
-0.056x | -258.82% |
| 2015-12-31 | €11.70 Million ≈ $13.68 Million |
€409.89K ≈ $479.21K |
0.035x | -- |
About Atrys Health SL
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of r… Read more